Rany Aburashed, DO

Neurologist · Clinical researcher · Healthcare executive

Dr. Rany Aburashed, DO

Founder and CEO of Neurogen Biomarking and Corporate Chief Medical Officer of Insight. Nearly two decades in neurology, multiple sclerosis research and hospital leadership, now focused on finding Alzheimer's risk earlier.

40+Phase 1–4 clinical trials as principal investigator
12Peer-reviewed papers indexed in PubMed
2026Albion College Distinguished Alumni Award
Dr. Rany Aburashed, DO, in a navy suit and copper tie
Founder & CEO Neurogen Biomarking

At-home Alzheimer's risk assessment with neurologist review.

Corporate Chief Medical Officer Insight

Also Corporate Chair of Specialty Services and Neurosciences.

President Insight Chicago Medical Group

Chicago, Illinois.

About

A neurologist who builds the systems around the patient

Dr. Rany Aburashed is an American neurologist, clinical researcher and healthcare executive. His career spans nearly two decades of patient care, clinical trials and institutional leadership, with a focus on multiple sclerosis, neuroimmunology and the biomarkers that show what is happening inside the nervous system before symptoms make it obvious.

He is the Founder and Chief Executive Officer of Neurogen Biomarking, which he started in 2024 to close the gap between memory concerns and an Alzheimer's diagnosis. At Insight, he serves as Corporate Chief Medical Officer, Corporate Chair of Specialty Services and Neurosciences, and President of Insight Chicago Medical Group.

Before Insight, he founded Memorial Healthcare's Institute for Neurosciences and Multiple Sclerosis in Owosso, Michigan, where he served as Chair of the Department of Neurology, Chair of Specialty Services and Director of the Multiple Sclerosis Comprehensive Center. He has been principal investigator on more than 40 Phase 1–4 clinical trials and is known for applying single-molecule array technology to protein biomarkers in multiple sclerosis.

A graduate of Albion College and the Michigan State University College of Osteopathic Medicine, he completed his neurology residency at Michigan State University and Sparrow Health System, where he was Chief Resident. Albion College named him a 2026 Distinguished Alumni Award recipient.

Career

Clinic, research and leadership

Leadership

  1. 2024 to present

    Founder & Chief Executive Officer

    Memory health company pairing at-home blood biomarker testing with digital cognitive assessment and neurologist review.

  2. Current

    Corporate Chief Medical Officer

    • Corporate Chair of Specialty Services and Neurosciences
    • President, Insight Chicago Medical Group
  3. Previously

    Founder, Institute for Neurosciences and Multiple Sclerosis

    Memorial Healthcare, Owosso, Michigan
    • Chair, Department of Neurology
    • Chair of Specialty Services
    • Director, Multiple Sclerosis Comprehensive Center
    • Member, Memorial Healthcare Board of Trustees

Education & training

  1. 2017

    Clinical Neuroimmunology Fellowship

    Memorial MS Center
  2. 2007 to 2010

    Neurology Residency

    Michigan State University / Sparrow Health System

    Chief Resident, Department of Neurology, 2009 to 2010.

  3. 2006 to 2007

    Transitional Internship

    Sparrow Hospital, Lansing, Michigan

    Department of Internal Medicine.

  4. 2002 to 2006

    Doctor of Osteopathic Medicine

    Michigan State University College of Osteopathic Medicine

    Recipient of the Michigan Medical Grant.

  5. 1998 to 2002

    Bachelor's degree in Psychology, with honors

    Albion College

    Additional study in world religion.

Neurogen Biomarking

Knowing Alzheimer's risk before the symptoms decide

Dr. Aburashed founded Neurogen Biomarking in 2024 after years of seeing patients and families reach a diagnosis late. The company's mission is to enable early detection of Alzheimer's risk with at-home testing and access to neurologists, so care can start while there is still time to act.

  1. 1An at-home blood test measures Alzheimer's-related biomarkers, including p-tau217.
  2. 2A digital cognitive assessment from Linus Health adds a measure of memory and thinking.
  3. 3A board-certified neurologist reviews the results with the patient by telehealth.

neurogenbiomarking.com

Dr. Rany Aburashed speaking at a podium in front of a Neurogen Biomarking screen
Dr. Aburashed speaking at a Neurogen Biomarking event.

Milestones

  1. Linus Health collaboration

    Digital cognitive assessments integrated into Neurogen's testing pathway.

    Business Wire
  2. Global agreement with Quanterix

    Quanterix blood biomarker assay adopted for Neurogen's patient-initiated blood test.

    GlobeNewswire
  3. NeuroX partnership

    Virtual neurology through NeuroX, a subsidiary of American TelePhysicians.

    HIT Consultant
  4. Data at AAIC 2025

    Neurogen research on its virtual care model presented at the Alzheimer's Association International Conference.

    HIT Consultant
  5. Tasso partnership

    Needle-free Tasso blood collection brought to the at-home testing platform.

    Business Wire
  6. Capillary p-tau217 study published

    Clinical performance of fingertip p-tau217 for remote triage, in Alzheimer's & Dementia. Dr. Aburashed is senior author.

    PubMed

Research

From multiple sclerosis to Alzheimer's biomarkers

Dr. Aburashed has served as principal investigator on more than 40 Phase 1–4 clinical trials, most in multiple sclerosis and neuroimmunology, covering disease-modifying therapies, treatment response and long-term outcomes. His research centers on precision disease management using neurofilament light chain and protein biomarker profiles, measured with single-molecule array technology. His work has appeared in Neurology: Neuroimmunology & Neuroinflammation, Multiple Sclerosis and Related Disorders and Alzheimer's & Dementia, and has been presented at ECTRIMS.

  • Multiple sclerosis
  • Neuroimmunology
  • Neurofilament light chain
  • Blood-based Alzheimer's biomarkers
  • Precision disease management
  • Neurodegenerative disease
  • Clinical trials

Selected publications

  1. Capillary brain-derived p-tau217 for remote triaging of Alzheimer's disease pathology: Clinical performance in a CLIA/CAP-certified laboratorySenior author
    Alzheimer's & Dementia, 2026 · Thijssen EH, Eghzawi A, et al., Aburashed R · PubMed
  2. Foreign Language Syndrome: Neurological and Psychiatric Aspects
    Neurology International, 2025 · Eghzawi A, Madha A, Aburashed R · PubMed
  3. Neurofilament Light Chain and Multiple Sclerosis: Building a Neurofoundational Model of Biomarkers and DiagnosisFirst author
    Neurology International, 2025 · Aburashed R, Eghzawi A, Long D, Pace R, Madha A, Cote J · PubMed
  4. Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab
    Multiple Sclerosis and Related Disorders, 2023 · Bar-Or A, Aburashed R, et al. · PubMed
  5. Interferon-β Decreases the Hypermetabolic State of Red Blood Cells from Patients with Multiple Sclerosis
    ACS Chemical Neuroscience, 2022 · Jacobs M, et al., Aburashed R, Spence D · PubMed
  6. Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies
    Neurology and Therapy, 2021 · Hunter SF, Aburashed RA, et al. · PubMed
  7. Malignant cerebral edema secondary to hyperammonemia in setting of acquired carnitine deficiency
    Neurology: Clinical Practice, 2020 · Long D, Derani T, Gheith T, Aburashed R, Saeed A · PubMed
  8. CNS-disseminated Angiostrongylus cantonensis mimicking atypical demyelinating diseaseSenior author
    Neurology: Neuroimmunology & Neuroinflammation, 2019 · Long D, Green K, Derani T, Decker N, Pace RJ, Aburashed R · PubMed
  9. Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment
    Journal of Investigative Medicine High Impact Case Reports, 2017 · Himedan M, et al., Aburashed R, Mao-Draayer Y · PubMed
  10. Cerebral venous and sinus thrombosis associated with subcutaneous immunoglobulin injection and oral contraceptive use
    Neurological Sciences, 2012 · Min J, Bhatt A, Aburashed R, Burton S · PubMed
  11. Hereditary neuropathy with liability to pressure palsies and amyotrophic lateral sclerosis
    Neurological Sciences, 2009 · Bhatt A, Farooq MU, Aburashed R, et al. · PubMed
  12. Therapeutic role of zonisamide in neuropsychiatric disorders
    Mini-Reviews in Medicinal Chemistry, 2008 · Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY · PubMed

All papers on PubMed

Recognition & service

Awards and honors

  • 2026
    Distinguished Alumni AwardAlbion College
  • 2024
    Notable Leaders in Health CareCrain's Chicago Business
  • 2018
    Physician Leadership RecognitionYoga Moves MS
  • 2018
    40 Under 40, nomineeCrain's Detroit Business
  • 2009
    Resident of the YearDepartment of Neurology, Michigan State University
  • 2006
    Richard L. Alper Memorial Award
  • 2005
    Student of the YearMichigan State University

He has also received Patients' Choice and Compassionate Doctor awards.

Boards, advisory work and teaching

Dr. Aburashed has served on the Memorial Healthcare Board of Trustees and the National Multiple Sclerosis Society Board of Trustees. His advisory and educational work includes engagements with Biogen, Genentech, Sanofi, Novartis and EMD Serono. He has trained medical students, neurology residents and fellows through bedside teaching, multiple sclerosis electives and lectures.

Dr. Rany Aburashed holding his glass Distinguished Alumni Award at an Albion College event
Receiving Albion College's 2026 Distinguished Alumni Award.
Dr. Rany Aburashed with three Neurogen Biomarking colleagues in front of the AAIC 2025 sign
With Neurogen colleagues at AAIC 2025.

Quick answers

Frequently asked

Who is Dr. Rany Aburashed?

Rany Aburashed, DO is an American neurologist, clinical researcher and healthcare executive. He is the Founder and CEO of Neurogen Biomarking and the Corporate Chief Medical Officer of Insight, where he is also Corporate Chair of Specialty Services and Neurosciences and President of Insight Chicago Medical Group.

What is Neurogen Biomarking?

Neurogen Biomarking is a memory health company Dr. Aburashed founded in 2024. It combines an at-home blood test for Alzheimer's-related biomarkers with a digital cognitive assessment and a review of results by a board-certified neurologist.

What is the Neurofoundational Model?

A conceptual teaching model from a 2025 Neurology International paper led by Dr. Aburashed. It uses the analogy of a house and its foundation to explain how changes in neurofilament light chain relate to nerve-cell injury in multiple sclerosis. The authors describe it as an educational tool, not a diagnostic test.

Where did Dr. Aburashed train?

He earned a bachelor's degree in psychology with honors from Albion College in 2002 and his Doctor of Osteopathic Medicine from the Michigan State University College of Osteopathic Medicine in 2006. He completed a transitional internship at Sparrow Hospital, a neurology residency at Michigan State University and Sparrow Health System, where he was Chief Resident, and a clinical neuroimmunology fellowship.

What is his clinical specialty?

Neurology, with subspecialty focus in neuroimmunology and multiple sclerosis. He is board certified in neurology by the American Board of Psychiatry and Neurology.

Contact

Media, speaking and partnerships

For interviews, speaking invitations and partnership inquiries, contact the Neurogen Biomarking media team or connect with Dr. Aburashed on LinkedIn.